Disappointing study results for Cerulean Pharma By: MarketMinute.com Stock News August 18, 2016 at 17:17 PM EDT Cerulean Pharma Inc. (Nasdaq: CERU) reported disappointing results from a Phase 2 study of CRLX101 sending the stock price plummeting $1.54 to close at $1.20.